MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HARP
Harpoon Therapeutics
HARP
|
+$59.1M |
| 2 |
TCRR
TCR2 Therapeutics
TCRR
|
+$52.1M |
| 3 |
EPZM
Epizyme
EPZM
|
+$34.6M |
| 4 |
G1 Therapeutics
GTHX
|
+$33.3M |
| 5 |
ARQL
Arqule
ARQL
|
+$12.7M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.51% |
| 2 | Miscellaneous | 5.49% |
Similar funds
MPM BioImpact's Q4 2019 Portfolio in Review
Q4 2019 is the first quarter with a 13F filing on record for MPM BioImpact, which disclosed 12 positions worth $282M. Its ten largest holdings account for 99% of the portfolio.
Its largest position is Harpoon Therapeutics: 389,842 shares worth $57.7M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Miscellaneous.
- MPM BioImpact's largest Q4 2019 buy was Harpoon Therapeutics: 389,842 shares worth $57.7M.
- MPM BioImpact's ten largest holdings make up 99% of its $282M portfolio in Q4 2019.
- MPM BioImpact disclosed 12 positions in Q4 2019, its first 13F filing on record.
Based on MPM BioImpact's 13F filing for Q4 2019, filed 14 Feb 2020.